전 세계 비경구 영양 시장 규모는 2023년부터 2029년까지 8.24%의 CAGR로 성장할 것으로 예상됩니다.
2023년, American Regent는 인산칼륨과 유사한 기능을 가진 인산칼륨 주사제 USP를 출시했습니다. FDA 승인을 받은 이 제품은 음식이나 수유 튜브를 통해 충분한 인을 섭취할 수 없는 어린이와 성인에게 정맥 주사액으로 인을 공급합니다. Otsuka Pharmaceutical Co., Ltd.는 2022년 일본 최초의 말초정맥영양제 'Enefluid®주'를 승인받았으며, 이 혁신적인 제품은 지방과 수용성 비타민, 포도당, 전해질, 아미노산을 이중 챔버 백에 혼합한 제품입니다. 이번 승인으로 회사의 제품 포트폴리오가 크게 강화되어 시장 성장에 기여했습니다.
2022년 Fresenius Kabi는 Ivenix, Inc.의 인수를 완료하여 미국 수액 치료 시장에서의 입지를 강화했습니다. 이번 인수를 통해 프레제니우스 카비의 비경구 영양 제품 라인업을 확장하고 환자, 고객 및 이해관계자에게 혜택을 제공하는 업계 최고의 종합적이고 프리미엄 수액 치료 제품을 제공하게 됐습니다.
2022년, 프레제니우스 카비(Fresenius Kabi)는 미국 소아 환자를 위한 지질 주사제(ILE)를 출시할 예정이라고 발표했습니다. 대상은 만삭아 및 미숙아 모두입니다. 이 제품은 모든 연령대의 비경구 영양에 사용하도록 승인된 최초이자 유일한 4유 지질 에멀전입니다.
헬스케어 업계가 영양 보충의 안전성, 효율성 및 비용 효율성을 중시하는 것을 반영하여 프리믹스 비경구 영양제(PN)의 사용이 증가하고 있습니다. 프리믹스 PN 솔루션은 바로 사용할 수 있는 표준화된 영양제이며, 의료 현장에서의 조제 및 수작업 조제의 필요성을 줄여줍니다. 이러한 편의성은 응급실, 구급실 등 신속한 대응이 필요한 병원이나 진료소에서 특히 유용합니다. 프리믹스 제제는 조제 과정을 간소화하고, 의료진의 시간을 절약하며, 환자의 안전에 중요한 영양소를 수작업으로 혼합할 때 발생할 수 있는 인적 오류의 위험을 줄여줍니다. 프리믹스 PN의 채택이 증가하는 주요 요인 중 하나는 프리믹스 제제가 제공하는 무균성과 안정성 향상입니다. 프리믹스 제제는 통제된 환경에서 제조되기 때문에 엄격한 품질 및 안전 기준을 충족하고 사내 배합으로 인한 오염 위험을 최소화합니다. 이러한 무균성은 혈류에 직접 투여되기 때문에 약간의 오염도 심각한 합병증을 유발할 수 있는 PN에서 특히 중요합니다. 의료 시설에서 프리믹스 PN을 사용하면 보관, 취급 및 운송이 용이합니다. 이러한 제제는 일반적으로 유통기한이 길고 포장이 표준화되어 있어 다양한 치료 환경에서 편리하고 다양하게 사용할 수 있습니다.
비경구 영양(PN) 시장의 주요 과제는 일부 새로운 기술과 제형의 효과와 안전성을 뒷받침할 수 있는 강력한 임상적 증거가 부족하다는 것입니다. 새로운 제형, 투여 시스템, 자동 조제 등의 혁신적 기술 등 PN의 발전은 잠재력을 가지고 있지만, 광범위한 임상시험과 장기 데이터 부족으로 인해 광범위한 도입이 제한되고 있습니다. 충분한 임상적 증거가 없으면 의료진은 새로운 기술을 환자 치료에 도입하는 것을 주저하고, 안전성이 입증된 기존 방법을 선호할 수 있습니다. 이로 인해 환자 결과를 개선하고 합병증을 줄이며 보다 개인화된 영양 지원을 제공할 수 있는 혁신적인 기술의 도입이 지연될 수 있습니다. 또한, 규제 당국은 이러한 새로운 기술을 승인하기 전에 더 많은 증거를 요구할 수 있으며, 이로 인해 시장 출시가 지연될 수 있습니다.
세계의 비경구 영양 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 영양별, 환자군별, 적응증별, 최종사용자별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.
The global parenteral nutrition market is expected to grow at a CAGR of 8.24% from 2023 to 2029.
RECENT VENDORS ACTIVITIES
KEY TAKEAWAYS
MARKET TRENDS & DRIVERS
Increased Utilization of Premixed PN Formulations
The utilization of premixed parenteral nutrition (PN) formulations is on the rise, reflecting the healthcare industry's focus on safety, efficiency, and cost-effectiveness in delivering nutritional support. Premixed PN solutions are standardized nutrient formulas that come ready for use, reducing the need for compounding or manual preparation in healthcare settings. This convenience is especially valuable in hospitals and clinics where rapid response is necessary, such as emergency or critical care departments. Premixed formulations simplify the preparation process, saving time for healthcare providers and reducing the risk of human error associated with the manual mixing of nutrients, which is critical for patient safety. One of the major drivers behind the increased adoption of premixed PN is the enhanced sterility and stability it offers. Since premixed formulations are manufactured in controlled environments, they meet rigorous quality and safety standards, minimizing the risk of contamination that can arise from in-house compounding. This sterility is particularly crucial in PN, where even slight contamination can lead to severe complications due to direct bloodstream delivery. For healthcare facilities, using premixed PN also allows for easier storage, handling, and transportation, as these formulations typically have longer shelf lives and standardized packaging, making them convenient and versatile in various care settings.
Growing Preference for Home Parenteral Nutrition (HPN)
The growing preference for Home Parenteral Nutrition (HPN) reflects a shift toward patient-centered, at-home care, offering essential nutritional support for patients with long-term needs, such as gastrointestinal disorders and malabsorption syndromes. HPN enhances comfort, flexibility, and quality of life by allowing patients to receive treatment at home, reducing hospital visits, and freeing up healthcare resources for acute care. Technological advancements, such as portable infusion pumps and remote monitoring tools, have made HPN safer and more manageable for patients and caregivers, enabling healthcare providers to oversee progress remotely. This trend is further driven by healthcare policies promoting cost-effective, patient-focused care. HPN reduces hospitalization expenses and provides a viable alternative for long-term nutritional support. Improved insurance coverage in many regions has increased its accessibility, making HPN an increasingly preferred option for both patients and healthcare systems.
Growing Prevalence of Premature Births
The increasing prevalence of premature births globally is driving the demand for specialized neonatal care, including parenteral nutrition (PN). Premature infants, born before 37 weeks of gestation, cannot often consume or absorb adequate nutrition orally or enterally due to underdeveloped gastrointestinal systems, making PN critical for their growth and development. Rising premature birth rates, particularly in regions like Sub-Saharan Africa and parts of the U.S., have highlighted the need for nutrient-rich PN solutions that support growth, brain development, and immune function during critical early life stages. To address these needs, advancements in PN formulations enriched with essential nutrients such as trace elements, fatty acids, and micronutrients have improved neonatal care quality. These innovations reduce complications like nutrient imbalances and liver disease, improving survival rates and long-term outcomes for preterm infants in neonatal intensive care units (NICUs). As premature birth rates continue to rise, the emphasis on improving PN quality and safety grows, ensuring better support for vulnerable infants.
INDUSTRY RESTRAINTS
Lack of Clinical Evidence to Support Novel Technology
A key challenge in the parenteral nutrition (PN) market is the lack of robust clinical evidence to support the efficacy and safety of some novel technologies and formulations. While advances in PN, such as new formulations, delivery systems, and innovations like automated compounding, hold potential, the absence of extensive clinical trials and long-term data limits their widespread adoption. Without sufficient clinical evidence, healthcare providers may hesitate to incorporate new technologies into patient care, preferring established methods with proven safety profiles. This can slow down the adoption of innovations that could potentially improve patient outcomes, reduce complications, or offer more personalized nutritional support. Furthermore, regulatory agencies may require more substantial evidence before approving these new technologies, delaying their availability to the market.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT
The global parenteral nutrition market by product is segmented into macronutrients, automated compounds, and micronutrients. The macronutrients segment accounted for the largest market share of 66% in 2023. In the parenteral nutrition (PN) market, macronutrients such as carbohydrates, lipids, and amino acids form the core of nutritional formulas aimed at patients with compromised digestive functions or specific nutrient needs. The demand for PN with balanced macronutrient compositions has grown with advancements in clinical understanding and patient-specific requirements. Multichamber bags (MCBs) are increasingly popular, as they contain glucose, amino acids, and lipids in pre-compounded formats, streamlining the preparation and reducing error risks in both inpatient and outpatient settings. These bags are available in dual- and tri-chamber forms, with the latter containing all three primary macronutrients, which reduces manipulation and supports safer administration. The focus on macronutrient optimization aligns with the broader trends in the PN market, which is projected to grow as clinicians and manufacturers work together to improve product safety, standardization, and personalized care options.
By Product
INSIGHTS BY NUTRITION
The global parenteral nutrition market by nutrition is categorized into RTU/standard commercial PN and compounded PN. The compounded PN segment shows prominent growth, with the fastest-growing CAGR of 10.33% during the forecast period. Compounded parenteral nutrition (PN) plays a critical role in the global parenteral nutrition market, providing tailored nutritional solutions for patients with specific medical needs. Unlike standardized PN formulas, compounded PN is custom-made, allowing healthcare providers to adjust macronutrients, micronutrients, and fluid volumes to meet individual patient requirements. This approach is especially valuable for patients with unique metabolic demands or complex health conditions, such as critically ill patients or those with organ dysfunction, who require precise nutrient management. The ability to personalize nutritional content enhances treatment efficacy, reduces the risk of nutrient imbalances, and improves overall patient outcomes, making compounded PN a growing segment within the broader PN market.
By Nutrition
INSIGHTS BY PATIENT GROUP
The global parenteral nutrition market by patient group is segmented into adults and pediatric. The adult segment dominates and holds the largest market share in 2023. The adult population relying on parenteral nutrition (PN) is growing due to conditions requiring intravenous nutritional support, such as short bowel syndrome, pancreatitis, Crohn's disease, and enterocutaneous fistulas. Total Parenteral Nutrition (TPN) is crucial for adults unable to absorb nutrients through the gastrointestinal tract. As malnutrition linked to various health issues rises, comprehensive nutritional assessments and TPN interventions are vital for improving patient outcomes. Standardized diagnostic frameworks will further enhance the management of adult malnutrition in healthcare systems.
By Patient Group
INSIGHTS BY INDICATION
Based on the indication, the short-term segment holds the largest share of the global parenteral nutrition market. The short-term parenteral nutrition (PN) market has evolved to address the metabolic needs of critically ill patients more effectively. Fat-based solutions, compared to glucose-heavy ones, reduce inflammation and stabilize blood sugar, suggesting they can mitigate risks like hyperglycemia. This advancement highlights the importance of tailoring PN to individual needs. Short-term PN serves as a bridge for patients requiring immediate stabilization, such as during preoperative bowel rest. However, PN's complexity demands strict oversight to prevent complications like infections and electrolyte imbalances. In lower-volume facilities, particularly U.S. hospitals, ensuring safety underscores the need for rigorous training and proper handling of formulations.
By Indication
INSIGHTS BY END-USER
Based on the end-user, the home care & long-term care settings segment shows significant growth with the fastest-growing CAGR of the global parenteral nutrition market during the forecast period. This growth is driven by the rising number of patients with chronic conditions who require long-term nutritional support but prefer to avoid hospital stays to improve their quality of life and reduce infection risks. Parenteral nutrition in-home care provides a cost-effective solution, allowing patients to manage their conditions comfortably while minimizing healthcare costs. Similarly, long-term care facilities, such as nursing homes, are increasingly adopting parenteral nutrition to support an aging population with complex health needs. Elderly patients with illnesses or age-related conditions that impair nutrient absorption rely on parenteral nutrition to maintain their health.
By End-Users
GEOGRAPHICAL ANALYSIS
North America dominates and holds the largest market share in the global parenteral nutrition market in 2023. This growth is driven by an increasing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, and short bowel syndrome, which necessitate nutritional support through parenteral methods when patients cannot ingest food orally. The market's growth is further supported by the rising rates of chronic diseases. Approximately 60% of adults in the U.S. live with at least one chronic condition, and this figure is projected to increase significantly, leading to greater reliance on parenteral nutrition to meet dietary needs during treatment. Overall, as healthcare systems adapt to these rising demands, the parenteral nutrition market in North America is poised for significant expansion in the coming years.
APAC accounted for the second-largest share of the global parenteral nutrition market and shows the highest growth during the forecast period. The parenteral nutrition (PN) market in the Asia-Pacific (APAC) region is experiencing rapid growth, fueled by increasing chronic disease prevalence, a rising aging population, and growing awareness about malnutrition's impact on health. Several APAC countries, including China, India, and Japan, are seeing significant investments in healthcare infrastructure, which, combined with government efforts to improve nutritional health, is accelerating the adoption of clinical nutrition solutions, particularly parenteral nutrition. Chronic diseases, such as cancer, diabetes, and gastrointestinal disorders, are prevalent across APAC.
By Geography
COMPETITIVE LANDSCAPE
The global parenteral nutrition market report contains exclusive data on 26 vendors. The market is marked by intense competition, driven by the presence of several key players, including Baxter, B. Braun, Fresenius Kabi, JW Pharmaceutical, Sichuan Kelun Pharmaceutical, and Grifols. These companies hold a significant share of the market and are known for their comprehensive parenteral nutrition portfolios. They focus on innovations to improve nutrient delivery systems, increase efficiency, and enhance patient outcomes. Local and regional players are also emerging, especially in developing markets, where the need for effective nutrition management solutions is increasing. In regions such as Asia-Pacific and Latin America, these players often offer cost-effective solutions that address local needs. Moreover, emerging companies are increasingly focusing on personalized nutrition solutions, which are designed to meet the specific metabolic needs of individual patients.
Key Vendors
Other Prominent Vendors
KEY QUESTIONS ANSWERED:
CHAPTER - 1: Parenteral Nutrition Market Overview
CHAPTER - 2: Parenteral Nutrition Market
CHAPTER - 3: Parenteral Nutrition Market Prospects & Opportunities
CHAPTER - 4: Parenteral Nutrition Market Segmentation Data
CHAPTER - 5: Key Regions Overview
CHAPTER - 6: Parenteral Nutrition Market Industry Overview
CHAPTER - 7: Appendix